The lancet oncology
-
The lancet oncology · Feb 2018
Randomized Controlled Trial Comparative StudyNeoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. ⋯ Novartis Pharmaceuticals Corporation.
-
The lancet oncology · Feb 2018
Comparative Study Controlled Clinical TrialSafety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest and typically short-lived. The oral anti-apoptotic B-cell lymphoma 2 protein inhibitor, venetoclax, has shown promising single-agent activity in patients with relapsed or refractory acute myeloid leukaemia and preclinical data suggested synergy between hypomethylating agents and venetoclax, which led to this combination phase 1b study. ⋯ AbbVie and Genentech.
-
The lancet oncology · Feb 2018
Randomized Controlled TrialDaratumumab for untreated multiple myeloma.
-
The lancet oncology · Feb 2018
Randomized Controlled Trial Comparative StudyImproved progression-free survival in metastatic breast cancer.
-
The lancet oncology · Feb 2018
Randomized Controlled TrialPEGPH20 for metastatic pancreatic ductal adenocarcinoma.